Intralymphatic Glutamic Acid Decarboxylase With Vitamin D Supplementation in Recent-Onset Type 1 Diabetes: A Double-Blind, Randomized, Placebo-Controlled Phase IIb Trial.
Johnny LudvigssonZdenek SumnikTerezie PelikanovaLia Nattero ChavezElena LundbergItxaso RicaMaria Asuncion Martinez-BroccaMarisol Ruiz de AdanaJeanette WahlbergAnastasia KatsarouRagnar HanasCristina HernandezMaria Clemente LeónAna Gómez-GilaMarcus LindMarta Ferrer LozanoTheo SasUlf SamuelssonStepanka PruhovaFabricia DietrichSara Puente MarinAnders NordlundUlf HanneliusRosaura CasasPublished in: Diabetes care (2021)
Intralymphatic administration of GAD-alum is a simple, well-tolerated treatment that together with vitamin D supplementation seems to preserve C-peptide in patients with recent-onset T1D carrying HLA DR3-DQ2. This constitutes a disease-modifying treatment for T1D with a precision medicine approach.